Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy
The outcomes of all RRMM patients who underwent T-cell apheresis for planned CAR-T therapy are described, to characterise the apheresis-to-infusion interval and the reasons for, and correlates of, failure to reach infusion, and to report progression-free survival (PFS) and overall survival (OS) anchored at the date of...